915410-93-4

Basic information

• Product Name: Benzene, 1,3-dibromo-5-[(4-methoxyphenyl)methoxy]-
• Synonyms: 3,5-dibromo-1-p-methoxy-benzyloxybenzene
• CAS NO: 915410-93-4
• Molecular Formula: C14H12Br2O2
• Molecular Weight: 372.056
• Mol File: 915410-93-4.mol

Chemical Properties

• Boiling Point: 410.3±35.0 °C(Predicted)
• Density: 1.614±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Benzene, 1,3-dibromo-5-[(4-methoxyphenyl)methoxy]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 1,3-dibromo-5-[(4-methoxyphenyl)methoxy]-(915410-93-4)
• EPA Substance Registry System: Benzene, 1,3-dibromo-5-[(4-methoxyphenyl)methoxy]-(915410-93-4)

Safety Data

• Hazardous Substances Data: 915410-93-4(Hazardous Substances Data)

Upstream product

• 827-94-1 2,6-dibromo-4-nitroaniline 
• 626-39-1 1,3,5-trisbromobenzene 
• 105-13-5 4-Methoxybenzyl alcohol 
• 626-41-5 3,5-dibromophenol 
• 2746-25-0 p-Methoxybenzyl bromide 
• 1435-51-4 1,3-dibromo-5-fluorobenzene 
• 6311-60-0 3,5-dibromonitrobenzene 

Downstream Products

• 915411-72-2 [3-Bromo-5-(4-methoxy-benzyloxy)-phenyl]-pyridin-4-yl-amine 
• 915410-95-6 N-(3-bromo-5-(4-methoxybenzyloxy)phenyl)pyridin-3-amine 
• 1068604-40-9 3-bromo-5-((p-methoxybenzyl)oxy)benzaldehyde 
• 915411-49-3 [3-bromo-5-(4-methoxy-benzyloxy)-phenyl]-(1-oxy-pyridin-3-yl)-amine 
• 915412-24-7 [3-bromo-5-(4-methoxy-benzyloxy)-phenyl]-(6-methoxy-pyridin-3-yl)-methanone 
• 915411-51-7 3-(1-oxy-pyridin-3-ylamino)-5-(1-triisopropylsilanyl-1H-indol-4-yl)-phenol 
• 915411-55-1 5-[3-hydroxy-5-(1-triisopropylsilanyl-1H-indol-4-yl)-phenylamino]-pyridin-2-ol 
• 915412-15-6 [3-(tert-butyl-diphenyl-silanyloxy)-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-pyridin-3-yl-amine 
• 915412-25-8 [3-(4-methoxy-benzyloxy)-5-(1-triisopropylsilanyl-1H-indol-4-yl)-phenyl]-(6-methoxy-pyridin-3-yl)-methanone 
• 915411-54-0 (6-benzyloxy-pyridin-3-yl)-[3-(4-methoxy-benzyloxy)-5-(1-triisopropylsilanyl-1H-indol-4-yl)-phenyl]-amine 
• 915412-16-7 [3-benzo[1,3]dioxol-4-yl-5-(tert-butyl-diphenyl-silanyloxy)-phenyl]-pyridin-3-yl-amine 
• 915411-50-6 [3-(4-methoxy-benzylooxy)-5-(1-triisopropylsilanyl-1H-indol-4-yl)-phenyl]-(1-oxy-pyridin-3-yl)-amine 

Relevant articles and documents

Process research on a phenoxybutyric acid LTB4 receptor antagonist. Efficient kilogram-scale synthesis of a 3,5-bisarylphenol core

An improved, kilogram-scale synthesis of a LTB4 receptor antagonist is reported. The title compound was prepared in four linear steps (seven steps total) and 54% overall yield. The 3,5-bisarylphenol core was obtained in nearly quantitative yield by the condensation of 1-benzotriazol-1-ylpropan-2-one with a chalcone. Although all the intermediates were oils, no chromatography purification was required.

Toward a total synthesis of divergolide A; Synthesis of the amido hydro- Quinone core and the C10-C15 fragment

A ring-closing metathesis (RCM) approach was envisioned for installing the E double bond at the C9 and C10 positions of divergolide A, isolated from a mangrove endophyte. Accordingly, the C10-C15 diene diol fragment and the amido hydroquinone core with the requisite functionalities and stereochemistry have been synthesized by using the norephedrine-based syn-selective glycolate aldol and the anti-selective aldol reactions, respectively. CuI-catalyzed amidation was employed to access the anilide intermediate, which was further transformed into the amido hydroquinone core. Copyright

Synthesis and pharmacological evaluation of N -(3-(1 H -Indol-4-yl)-5-(2- methoxyisonicotinoyl)phenyl)methanesulfonamide (LP-261), a potent antimitotic agent

The synthesis and optimization of a series of orally bioavailable 1-(1H-indol-4-yl)-3,5-disubstituted benzene analogues as antimitotic agents are described. A functionalized dibromobenzene intermediate was used as a key scaffold, which when modified by sequential Suzuki coupling and Buchwald-Hartwig amination provided a flexible entry to 1,3,5-trisubstituted phenyl compounds. A 1H-indol-4-yl moiety at the 1-position was determined to be a critical feature for optimal potency. The compounds have been shown to induce cell cycle arrest at the G2/M phase and demonstrate efficacy in both cell viability and cell proliferation assays. The primary site of action for these agents is revealed by their colchicine competitive inhibition of tubulin polymerization, and a computational model has been developed for the association of these compounds to tubulin. An optimized lead LP-261 significantly inhibits growth of a human non-small-cell lung tumor (NCI-H522) in a mouse xenograft model.

A synthesis of 3,5-disubstituted phenols

Robust and scalable syntheses of some synthetically useful 3,5- disubstituted phenols are presented. The process involves the selective displacement of a halogen by nucleophilic aromatic substitution using a preformed mixture of potassium tert-butoxide and p-methoxybenzyl alcohol (PMB-OH), followed by deprotection of the PMB ether with acid in the presence of 1,3-dimethoxybenzene. These processes have been demonstrated on kilogramscale, providing crystalline phenols in good yield and high purity.

LEUKOTRIENE B4 INHIBITORS

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, COPD

PROCESS FOR PREPARING TRIAZOLONES

The present process provides a improved method for the preparation of alkylsulfanyl substituted triazoles 2 which are useful intermediates in a new process for the preparation of triazolones

Anti-cancer agents and uses thereof

The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula I: and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3-R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6-10 carbons in the ring portion, an optionally-substituted 6-membered heteroaryl group having 1-3 nitrogen atoms in the ring portion, an optionally-substituted 5-membered heteroaryl group having 0-4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6-membered ring is fused either to a 5-membered ring or to a 6-membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, prostate, non-small cell lung and colon. They are additionally useful in the treatment of proliferative retinopathies such as diabetic neuropathy and macular degeneration.

ANTI-CANCER AGENTS ANS USES THEREOF

The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula (I): and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3 R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6- 10 carbons in the ring portion, an optionally-substituted 6- membered heteroaryl group having 1- 3 nitrogen atoms in the ring portion, an optionally-substituted 5- membered heteroaryl group having 0- 4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6- membered ring is fused either to a 5- membered ring or to a 6- membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, prostate, non-small cell lung and colon. They are additionally useful in the treatment of proliferative retinopathies such as diabetic neuropathy and macular degeneration.

Anti-cancer agents and uses thereof

The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula I: and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3—R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6-10 carbons in the ring portion, an optionally-substituted 6-membered heteroaryl group having 1-3 nitrogen atoms in the ring portion, an optionally-substituted 5-membered heteroaryl group having 0-4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6-membered ring is fused either to a 5-membered ring or to a 6-membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, non-small cell lung and colon.